Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019 to 2025
Asset Purchase Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2019 to 2025
Asset Purchase Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.
The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
The report focuses on four primary types of asset available for purchase:
- Business assets
- Product assets
- Royalty assets
- Technology assets
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of asset purchase deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of asset purchase deals.
Chapter 4 provides a review of the leading asset purchase deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active asset purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of asset purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.
The deal directory includes a comprehensive listing of all asset purchase deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in asset purchase dealmaking since 2019.
In conclusion, this report provides everything a prospective dealmaker needs to know about asset purchase alliances.
Key benefits
Asset Purchase Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:
- Understand deal trends since 2019
- Browse asset purchase deals
- Benchmark analysis – identify market value of transactions
- Financials - headline, upfront, milestone, royalty rates
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report scope
Asset Purchase Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.
Asset Purchase Deals in Pharmaceuticals and Biotechnology includes:
- Trends in asset purchase dealmaking in the biopharma industry
- Overview of asset purchase deal structure
- Directory of asset purchase deal records covering pharmaceuticals and biotechnology
- The leading asset purchase deals by value
- Most active asset purchase dealmakers
- The leading asset purchase partnering resources
The available deals are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Technology type
Each deal title links via hyperlink to an online version of the actual deal record, providing easy access to each contract document where available.
Asset Purchase Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for asset purchase deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the rights granted or optioned?
- What rights are granted by the agreement?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are intellectual property rights handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Asset Purchase Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:
- Understand deal trends since 2019
- Browse asset purchase deals
- Benchmark analysis – identify market value of transactions
- Financials - headline, upfront, milestone, royalty rates
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in asset purchase dealmaking
2.1. Introduction
2.2. Types of assets purchased
2.3. Trends in asset purchase deals since 2019
2.3.1. Asset purchase dealmaking by year, 2019-2025
2.3.2. Asset purchase dealmaking by phase of development, 2019-2025
2.3.3. Asset purchase dealmaking by industry sector, 2019-2025
2.3.4. Asset purchase dealmaking by therapy area, 2019-2025
2.3.5. Asset purchase dealmaking by technology type, 2019-2025
2.3.6. Asset purchase dealmaking by most active company, 2019-2025
2.4. Reasons for entering into asset purchase partnering deals
2.4.1. Business assets
2.4.2. Product assets
2.4.3. Royalty assets
2.4.4. Technology assets
2.5. The future of asset purchase deals
Chapter 3 – Overview of asset purchase deal structure
3.1. Introduction
3.2. Asset purchase agreement structure
Chapter 4 – Leading asset purchase deals
4.1. Introduction
4.2. Top asset purchase deals by value
Chapter 5 – Top 25 most active asset purchase dealmakers
5.1. Introduction
5.2. Top 25 most active asset purchase dealmakers
Chapter 6 – Asset purchase deals including contracts directory
6.1. Introduction
6.2. Asset purchase deals with contracts 2019-2025
Deal directory
Deal directory – Asset purchase dealmaking by companies A-Z
Deal directory – Asset purchase dealmaking by therapy area
Deal directory – Asset purchase dealmaking by technology type
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of assets purchased
Figure 2: Trends in asset purchase deal announcements, 2019-2025
Figure 3: Asset purchase deals signed at each phase of development, 2019-2025
Figure 4: Asset purchase deals by industry sector, 2019-2025
Figure 5: Asset purchase deals by therapy area, 2019-2025
Figure 6: Asset purchase deals by technology type, 2019-2025
Figure 7: Top 25 most active asset purchase dealmakers, 2019-2025
Figure 8: Top asset purchase deals by value, 2019-2025
Figure 9: Most active asset purchase dealmakers, 2019-2025
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $7,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Biopharma Research Ltd based in York, United Kingdom. We have been trading successfully online since 2012 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from primary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.
